iQure Pharma Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.79M
- Investors
-
8
iQure Pharma General Information
Description
Developer of biopharmaceutical therapies designed to address central nervous system disorders by restoring glutamate homeostasis. The company focuses on enhancing astrocytic regulation of glutamate uptake to maintain synaptic balance and protect neurons from overstimulation, enabling the prevention of excitotoxicity-driven neuronal damage and disease progression across a broad range of neurological conditions.
Contact Information
Website
www.iqurepharma.comCorporate Office
- 475 Wall Street
- Princeton, NJ 08540
- United States
Corporate Office
- 475 Wall Street
- Princeton, NJ 08540
- United States
iQure Pharma Timeline
iQure Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 21-Sep-2026 | $2.79M | Completed | Clinical Trials - Phase 1 | ||
| 5. Later Stage VC (Series B1) | 03-Nov-2025 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 20-Dec-2024 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A2) | 14-Dec-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A1) | 31-Aug-2022 | $1.45M | $1.45M | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 01-Jan-2022 | Completed | Startup |
iQure Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series A-2 | 1,419,231 | $0.000100 | $1.36 | $1.36 | 1x | $1.36 | 18.02% | |
| Series A-1 | 995,170 | $0.000100 | $1.46 | $1.46 | 1x | $1.46 | 12.63% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
iQure Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
iQure Pharma Patents
iQure Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202500236-D0 | A novel treatment for dravet syndrome | Pending | 09-Jan-2025 | ||
| GB-2704067-A | A novel treatment for dravet syndrome | Pending | 09-Jan-2025 | ||
| WO-2026150001-A1 | Positive allosteric modulator (pam) of the eaat2/glt-1 glutamate transporter for use in the treatment or prevention of dravet syndrome | Pending | 09-Jan-2025 | A61P25/08 |
iQure Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
iQure Pharma Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| i&i Biotech Fund | Venture Capital | Minority | ||
| Mass Medical Angels | Angel Group | Minority | ||
| OKG Capital | Venture Capital | Minority | ||
| SideCar Angels | Angel Group | Minority | ||
| Ventura BioMed Investors | Venture Capital | Minority |
iQure Pharma FAQs
-
When was iQure Pharma founded?
iQure Pharma was founded in 2019.
-
Where is iQure Pharma headquartered?
iQure Pharma is headquartered in Princeton, NJ.
-
What is the size of iQure Pharma?
iQure Pharma has 9 total employees.
-
What industry is iQure Pharma in?
iQure Pharma’s primary industry is Drug Discovery.
-
Is iQure Pharma a private or public company?
iQure Pharma is a Private company.
-
What is iQure Pharma’s current revenue?
The current revenue for iQure Pharma is .
-
How much funding has iQure Pharma raised over time?
iQure Pharma has raised $15.9M.
-
Who are iQure Pharma’s investors?
i&i Biotech Fund, Mass Medical Angels, OKG Capital, SideCar Angels, and Ventura BioMed Investors are 5 of 8 investors who have invested in iQure Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
